Table 2.
Cell line |
Sensitivity to gemcitabine in cell line1 |
|||
IC50 (μmol/L) | IC60 (μmol/L) | IC70 (μmol/L) | IC80 (μmol/L) | |
NCC-CC1 | 86.78 | N.A | N.A | N.A |
NCC-CC3-1 | 0.04 | 1.82 | 9.31 | 85.21 |
NCC-CC3-2 | 0.10 | 1.92 | 43.83 | N.A |
NCC-CC4-1 | 0.05 | 4.08 | N.A | N.A |
NCC-CC4-2 | 0.03 | 11.53 | N.A | N.A |
NCC-CC4-3 (NCC-CC5) | 0.06 | 4.92 | 95.10 | N.A |
NCC-CC6-1 | 0.01 | 0.02 | 0.06 | 3.76 |
NCC-CC6-2 | 10.98 | 35.67 | N.A | N.A |
NCC-BD1 | 7.66 | 58.00 | N.A | N.A |
NCC-BD2 | N.A | N.A | N.A | N.A |
NCC-BD3 | N.A | N.A | N.A | N.A |
NCC-BD4-1 | 0.04 | 0.06 | 0.09 | 2.93 |
NCC-BD4-2 | 0.06 | 0.07 | 0.19 | 5.37 |
The cytotoxicity of gemcitabine for each cell line was assessed by a modified 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay with CellTiter 96 Aqueous One Solution Reagent (Promega, Madison, WI, United States). Tumor cells (3000 cells⁄well) in the exponential growth phase were grown in 96-well plates. IC: Inhibitory concentration.